{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:37Z","timestamp":1787026537881,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL). Here, we evaluated the antitumor activities of CD38\/CD47 bispecific antibodies (BsAbs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Five suitable anti-CD38 antibodies for co-targeting CD47 and CD38 BsAb were developed using a 2 + 2 \u201cmAb-trap\u201d platform. The activity characteristics of the CD38\/CD47 BsAbs were evaluated using\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      systems.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using hybridoma screening technology, we obtained nine suitable anti-CD38 antibodies. All anti-CD38 antibodies bind to CD38\n                      <jats:sup>+<\/jats:sup>\n                      tumor cells and kill tumor cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Five anti-CD38 antibodies (4A8, 12C10, 26B4, 35G5, and 65A7) were selected for designing CD38\/CD47 BsAbs (IMM5605) using a \u201cmAb-trap\u201d platform. BsAbs had higher affinity and binding activity to the CD38 target than those to the CD47 target, decreasing the potential on-target potential and off-tumor effects. The CD38\/CD47 BsAbs did not bind to RBCs and did not induce RBC agglutination; thus, BsAbs had much lower blood toxicity. The CD38\/CD47 BsAbs had a greater ability to block the CD47\/SIRP\u03b1 signal in CD38\n                      <jats:sup>+<\/jats:sup>\n                      \/CD47\n                      <jats:sup>+<\/jats:sup>\n                      tumor cells than IMM01 (SIRP\u03b1 Fc fusion protein). Through Fc domain engineering, CD38\/CD47 BsAbs were shown to kill tumors more effectively by inducing ADCC and ADCP. IMM5605\u201326B4 had the strongest inhibitory effect on cellular CD38 enzymatic activity. IMM5605\u201312C10 had the strongest ability to directly induce the apoptosis of tumor cells. The anti-CD38 antibody 26B4 combined with the SIRP\u03b1-Fc fusion proteins showed strong antitumor effects, which were better than any of the mono-therapeutic agents used alone in the NCI-H929 cell xenograft model. The CD38\/CD47 BsAbs exhibited strong antitumor effects; specifically, IMM5605\u201312C10 efficiently eradicated all established tumors in all mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A panel of BsAbs targeting CD38 and CD47 developed based on the \u201cmAb-tarp\u201d platform showed potent tumor-killing ability\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      . As BsAbs had lower affinity for binding to CD47, higher affinity for binding to CD38, no affinity for binding to RBCs, and did not induce RBC agglutination, we concluded that CD38\/CD47 BsAbs are safe and have a satisfactory tolerability profile.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1398508","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:21:26Z","timestamp":1719274886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38"],"prefix":"10.3389","volume":"15","author":[{"given":"Song","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.11.1643","article-title":"Identification and characterization of an active soluble form of human cd38 in normal and pathological fluids","volume":"8","author":"Funaro","year":"1996","journal-title":"Int Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0145\u20132126(00)00093-x","article-title":"Human cd38: A (R)Evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"Cd38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20135472.Can-14\u20133639","article-title":"Cd38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"Cd19+Cd24hicd38hi B cells maintain regulatory T cells while limiting th1 and th17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015\u201312-687749","article-title":"Daratumumab depletes cd38+ Immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B7","first-page":"99","article-title":"Cd38\/cd31, a receptor\/ligand system ruling adhesion and signaling in human leukocytes","volume":"75","author":"Deaglio","year":"2000","journal-title":"Chem Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic adp-ribose catalyzed by lymphocyte antigen cd38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R500012200","article-title":"Nicotinic acid adenine dinucleotide phosphate (Naadp)-mediated calcium signaling","volume":"280","author":"Lee","year":"2005","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123924","article-title":"Monoclonal antibodies for the treatment of multiple myeloma: an update","volume":"19","author":"Abramson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0962\u20138924(00)01906\u20131","article-title":"Integrin-associated protein (Cd47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713\u2013120142","article-title":"The interaction between signal regulatory protein alpha (Sirp\u03b1) and cd47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The cd47-signal regulatory protein alpha (Sirpa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045\u2013020-00930\u20131","article-title":"Role of cd47 in hematological Malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"Cd47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-cd47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14712598.2020.1685976","article-title":"Blockade of the cd47-sirp\u03b1 Axis: A promising approach for cancer immunotherapy","volume":"20","author":"Uger","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022\u2013164755","article-title":"Exploration of the therapeutic effects of cd47 and cd38 antibody combination in relapsed or refractory multiple myeloma (Rrmm) and the correlation with cd47 and cd38 expression","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022\u2013157585","article-title":"A phase 1\/2, first-in-human, multicenter, open-label, dose escalation and dose-expansion study of single-agent isb 1442 in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Sia","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with cd47 blockade prolongs survival in preclinical models of pediatric T-all","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022\u2013162201","article-title":"Preclinical evaluation of isb 1442, a first-in-class cd38 and cd47 bispecific antibody innate cell modulator for the treatment of aml and T-all","volume":"140","author":"Stefano","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5117","article-title":"Immunotherapy in hematologic Malignancies","volume":"27","author":"Kansara","year":"2020","journal-title":"Curr Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004453C","article-title":"The promise and perils of immunotherapy","volume":"5","author":"Lesch","year":"2021","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1309\/11j6\u20130u42-vf4e-wa02","article-title":"Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples","volume":"118","author":"Xu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0145\u20132126(99)00147\u20132","article-title":"Increased cd38 expression is associated with favorable prognosis in adult acute leukemia","volume":"24","author":"Keyhani","year":"2000","journal-title":"Leuk Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3180959e09","article-title":"Characteristic expression patterns of tcl1, cd38, and cd44 identify aggressive lymphomas harboring a myc translocation","volume":"32","author":"Rodig","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic cd38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 Receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"Sar650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.Ccr-16\u20133192","article-title":"Targeting cd38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22992","article-title":"Targeting cd38 alleviates tumor-induced immunosuppression","volume":"8","author":"Tai","year":"2017","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-sirp\u03b1 Antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20135472.Can-10\u20132238","article-title":"Therapeutic antibody targeting of cd47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.09.040191.001543","article-title":"The scid mouse mutant: definition, characterization, and potential uses","volume":"9","author":"Bosma","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.Ccr-14\u20130695","article-title":"Sar650984, a novel humanized cd38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other cd38+ Hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045\u2013022-01385\u20132","article-title":"Sirp\u03b1-fc fusion protein imm01 exhibits dual anti-tumor activities by targeting cd47\/sirp\u03b1 Signal pathway via blocking the \"Don't eat me\" Signal and activating the \"Eat me\" Signal","volume":"15","author":"Yu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2013022-01805\u20139","article-title":"Imm0306, a fusion protein of cd20 mab with the cd47 binding domain of sirp\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and nk cells via blockade of cd47-sirp\u03b1 Interaction and fc\u0263r engagement by simultaneously binding to cd47 and cd20 of B cells","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:21:30Z","timestamp":1719274890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1398508"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1398508","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"article-number":"1398508"}}